Priavoid

Company Overview

Priavoid is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders driven by protein misfolding and aggregation.

The company’s strategy centers on targeting the root cause of neurodegenerative diseases: toxic oligomeric protein aggregates that disrupt neuronal function. Its therapeutics are designed to directly interact with and dismantle these aggregates, rather than simply slowing downstream effects.

Priavoid operates as a platform-driven biotech, applying a single mechanistic approach across multiple neurodegenerative indications, with an emphasis on disease modification rather than symptomatic treatment.

Headquarters and Global Presence

• headquartered in Düsseldorf, Germany
• operates with a European base and collaborates with academic institutions and research organizations globally

The company maintains a focused structure, advancing clinical programs primarily through partnerships and grant-supported initiatives.

Founding and History

• founded in 2017 as a spin-out from Heinrich Heine University Düsseldorf and Forschungszentrum Jülich

Priavoid was established to translate academic research on protein aggregation and peptide chemistry into therapeutic development.

The company has raised early-stage funding from venture investors and public sources, supporting its transition into clinical development.

Therapy Areas and Focus

Priavoid focuses on neurodegenerative diseases.

Key areas include:

• Alzheimer’s disease
• Parkinson’s disease and related synucleinopathies
• amyotrophic lateral sclerosis (ALS)
• tauopathies and other protein aggregation disorders

The company prioritizes diseases with high unmet need and limited disease-modifying treatment options.

Technology Platforms and Modalities

The company’s platform is based on all-D-peptide therapeutics.

Key components include:

• peptides composed of D-amino acids (mirror-image peptides)
• mirror-image phage display and structure-based design
• anti-oligomeric “detangler” mechanism targeting protein aggregates
• oral bioavailability and blood-brain barrier penetration

These compounds are designed to bind toxic oligomers and disassemble them into non-toxic monomers, interrupting disease progression at a fundamental biological level.

Key Pipeline and Programs

PRI-002

• Modality: oral all-D-peptide
• Target: amyloid-beta oligomers
• Indication: Alzheimer’s disease
• Status: Phase 2 clinical development
• Mechanism: disassembly of toxic amyloid aggregates

PRI-101

• Modality: all-D-peptide
• Target: alpha-synuclein
• Indication: Parkinson’s disease and related disorders
• Status: preclinical development

PRI-200

• Modality: all-D-peptide
• Target: tau protein
• Indication: tauopathies
• Status: preclinical development

Additional programs

• Modality: all-D-peptide therapeutics
• Indication focus: broader neurodegenerative diseases including ALS
• Status: discovery stage

The pipeline reflects a platform approach targeting multiple aggregation-driven diseases.

Key Personnel

• Philipp Bürling, Chief Executive Officer
• Prof. Dr. Dieter Willbold, Chief Scientific Officer
• Prof. Dr. Oliver Peters, Chief Medical Officer

The leadership team includes experts in peptide chemistry, neuroscience and clinical development.

Strategic Partnerships

Priavoid operates with a collaboration-supported model.

Key elements include:

• academic collaborations with Forschungszentrum Jülich and university partners
• funding support from organizations such as the Alzheimer’s Association and Michael J. Fox Foundation
• participation in accelerator programs and public research initiatives

These relationships support both discovery and clinical advancement.

FAQ Section